Skip to main content
Top
Published in: Critical Care 6/2014

Open Access 01-12-2014 | Research

Diagnostic and prognostic value of neutrophil gelatinase-associated lipocalin, matrix metalloproteinase-9, and tissue inhibitor of matrix metalloproteinases-1 for sepsis in the Emergency Department: an observational study

Authors: Miaomiao Wang, Qian Zhang, Xin Zhao, Guijuan Dong, Chunsheng Li

Published in: Critical Care | Issue 6/2014

Login to get access

Abstract

Introduction

The aim of this study was to evaluate the early diagnostic, risk stratification and prognostic value of neutrophil gelatinase-associated lipocalin (NGAL), matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinases-1 (TIMP-1), compared with procalcitonin (PCT) and the Mortality in Emergency Department Sepsis (MEDS) score in septic patients in the emergency department (ED).

Methods

In total, 480 consecutive adult patients were enrolled in this study. They fulfilled the systemic inflammatory response syndrome (SIRS) criteria and were admitted to the ED of Beijing Chaoyang Hospital from February 2013 to August 2013. A total of 40 healthy controls comprised the control group. The patients were classified into four groups: SIRS, sepsis, severe sepsis, and septic shock. Serum NGAL, MMP-9, TIMP-1 and PCT were measured, and MEDS score was calculated at enrollment. The prognostic values of NGAL, MMP-9 and TIMP-1 were compared with PCT and MEDS score. A 28-day follow-up was performed for all patients.

Results

The median levels of serum NGAL and TIMP-1 increased with sepsis severity. The areas under the receiver operating characteristic (AUC) curves of NGAL or TIMP-1 were greater than those of PCT and MEDS score in diagnosing and predicting 28-day mortality, and the AUC of a combination of NGAL and MEDS score or TIMP-1 and MEDS score was more significant. Serum NGAL, MMP-9 and TIMP-1 levels were significantly higher in non-survivors than survivors at 28 days’ follow-up. In addition, the level of NGAL was much higher in septic patients with acute kidney injury (AKI) than those without AKI. NGAL, TIMP-1, MMP-9 and MEDS score were found to be independent predictors of 28-day mortality in septic patients. The levels of serum NGAL and TIMP-1 were positively correlated with PCT and MEDS score in every septic group.

Conclusions

NGAL and TIMP-1 are valuable for the risk stratification, early diagnosis and prognostication of sepsis in the ED. NGAL is also a valuable biomarker for prognosis of septic patients with AKI in the ED.
Appendix
Available only for authorised users
Literature
1.
go back to reference Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R: Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013, 41: 580-637. 10.1097/CCM.0b013e31827e83af.CrossRef Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R: Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013, 41: 580-637. 10.1097/CCM.0b013e31827e83af.CrossRef
2.
go back to reference Strehlow MC, Emond SD, Shapiro NI, Pelletier AJ, CamargoJr CA: National study of emergency department visits for sepsis, 1992 to 2001. Ann Emerg Med. 2006, 48: 326-331. 10.1016/j.annemergmed.2006.05.003.CrossRef Strehlow MC, Emond SD, Shapiro NI, Pelletier AJ, CamargoJr CA: National study of emergency department visits for sepsis, 1992 to 2001. Ann Emerg Med. 2006, 48: 326-331. 10.1016/j.annemergmed.2006.05.003.CrossRef
3.
go back to reference Schmidt-Ott KM, Mori K, Li JY, Kalandadze A, Cohen DJ, Devarajan P, Barasch J: Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol. 2007, 18: 407-413. 10.1681/ASN.2006080882.CrossRef Schmidt-Ott KM, Mori K, Li JY, Kalandadze A, Cohen DJ, Devarajan P, Barasch J: Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol. 2007, 18: 407-413. 10.1681/ASN.2006080882.CrossRef
4.
go back to reference Mori K, Nakao K: Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage. Kidney Int. 2007, 71: 967-970. 10.1038/sj.ki.5002165.CrossRef Mori K, Nakao K: Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage. Kidney Int. 2007, 71: 967-970. 10.1038/sj.ki.5002165.CrossRef
5.
go back to reference Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK: The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell. 2002, 10: 1033-1043. 10.1016/S1097-2765(02)00708-6.CrossRef Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK: The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell. 2002, 10: 1033-1043. 10.1016/S1097-2765(02)00708-6.CrossRef
6.
go back to reference Hoffmann U, Brueckmann M, Borggrefe M: Matrix metalloproteinases and their inhibitors: promising novel biomarkers in severe sepsis?. J Crit Care. 2009, 13: 1006-10.1186/cc8156.CrossRef Hoffmann U, Brueckmann M, Borggrefe M: Matrix metalloproteinases and their inhibitors: promising novel biomarkers in severe sepsis?. J Crit Care. 2009, 13: 1006-10.1186/cc8156.CrossRef
7.
go back to reference M hl D, Nagy B, Woth G, Falusi B, Bogár L, Weber G, Lantos J: Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis. J Crit Care. 2011, 26: 550-555. 10.1016/j.jcrc.2011.02.011.CrossRef M hl D, Nagy B, Woth G, Falusi B, Bogár L, Weber G, Lantos J: Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis. J Crit Care. 2011, 26: 550-555. 10.1016/j.jcrc.2011.02.011.CrossRef
8.
go back to reference Vanlaere I, Libert C: Matrix metalloproteinases as drug targets in infections caused by gram-negative bacteria and in septic shock. Clin Microbiol Rev. 2009, 22: 224-239. 10.1128/CMR.00047-08.CrossRef Vanlaere I, Libert C: Matrix metalloproteinases as drug targets in infections caused by gram-negative bacteria and in septic shock. Clin Microbiol Rev. 2009, 22: 224-239. 10.1128/CMR.00047-08.CrossRef
9.
go back to reference Barresi V, Reggiani-Bonetti L, Di Gregorio C, Vitarelli E, Ponz De Leon M, Barresi G: Neutrophil gelatinase-associated lipocalin (NGAL) and matrix metalloproteinase-9 (MMP-9) prognostic value in stage I colorectal carcinoma. Pathol Res Pract. 2011, 207: 479-486. 10.1016/j.prp.2011.05.012.CrossRef Barresi V, Reggiani-Bonetti L, Di Gregorio C, Vitarelli E, Ponz De Leon M, Barresi G: Neutrophil gelatinase-associated lipocalin (NGAL) and matrix metalloproteinase-9 (MMP-9) prognostic value in stage I colorectal carcinoma. Pathol Res Pract. 2011, 207: 479-486. 10.1016/j.prp.2011.05.012.CrossRef
10.
go back to reference Lorente L, Martín MM, Solé-Violán J, Blanquer J, Labarta L, Díaz C, Borreguero-León JM, Orbe J, Rodríguez JA, Jiménez A, Páramo JA: Association of sepsis-related mortality with early increase of TIMP-1/MMP-9 ratio. PLoS One. 2014, 9: e94318-10.1371/journal.pone.0094318.CrossRef Lorente L, Martín MM, Solé-Violán J, Blanquer J, Labarta L, Díaz C, Borreguero-León JM, Orbe J, Rodríguez JA, Jiménez A, Páramo JA: Association of sepsis-related mortality with early increase of TIMP-1/MMP-9 ratio. PLoS One. 2014, 9: e94318-10.1371/journal.pone.0094318.CrossRef
11.
go back to reference Kim H, Hur M, Cruz DN, Moon H-W, Yun Y-M: Plasma neutrophil gelatinase-associated lipocalin as a biomarker for acute kidney injury in critically ill patients with suspected sepsis. Clin Biochem. 2013, 46: 1414-1418. 10.1016/j.clinbiochem.2013.05.069.CrossRef Kim H, Hur M, Cruz DN, Moon H-W, Yun Y-M: Plasma neutrophil gelatinase-associated lipocalin as a biomarker for acute kidney injury in critically ill patients with suspected sepsis. Clin Biochem. 2013, 46: 1414-1418. 10.1016/j.clinbiochem.2013.05.069.CrossRef
12.
go back to reference Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: International Sepsis Definitions Conference:SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Intensive Care Med. 2003, 29: 530-538. 10.1007/s00134-003-1662-x.CrossRef Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: International Sepsis Definitions Conference:SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Intensive Care Med. 2003, 29: 530-538. 10.1007/s00134-003-1662-x.CrossRef
13.
go back to reference Zhang Q, Dong G, Zhao X, Wang M, Li CS: Prognostic significance of hypothalamic-pituitary-adrenal axis hormones in early sepsis: a study performed in the emergency department. Intensive Care Med. 2014, 40: 1499-1508. 10.1007/s00134-014-3468-4.CrossRef Zhang Q, Dong G, Zhao X, Wang M, Li CS: Prognostic significance of hypothalamic-pituitary-adrenal axis hormones in early sepsis: a study performed in the emergency department. Intensive Care Med. 2014, 40: 1499-1508. 10.1007/s00134-014-3468-4.CrossRef
14.
go back to reference Shapiro NI, Wolfe RE, Moore RB, Smith E, Burdick E, Bates DW: Mortality in emergency department sepsis (MEDS) scores: a prospectively derived and validated clinical prediction rule. Crit Care Med. 2003, 31: 670-675. 10.1097/01.CCM.0000054867.01688.D1.CrossRef Shapiro NI, Wolfe RE, Moore RB, Smith E, Burdick E, Bates DW: Mortality in emergency department sepsis (MEDS) scores: a prospectively derived and validated clinical prediction rule. Crit Care Med. 2003, 31: 670-675. 10.1097/01.CCM.0000054867.01688.D1.CrossRef
15.
go back to reference Fliser D, Laville M, Covic A, Fouque D, Vanholder R, Juillard L, Van Biesen W: A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: Part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant. 2012, 27: 4263-4272. 10.1093/ndt/gfs375.CrossRef Fliser D, Laville M, Covic A, Fouque D, Vanholder R, Juillard L, Van Biesen W: A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: Part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant. 2012, 27: 4263-4272. 10.1093/ndt/gfs375.CrossRef
16.
go back to reference Howell MD, Donnino MW, Talmor D, Clardy P, Ngo L, Shapiro NI: Performance of severity of illness scoring systems in emergency department patients with infection. Acad Emerg Med. 2007, 14: 709-714. 10.1111/j.1553-2712.2007.tb01866.x.CrossRef Howell MD, Donnino MW, Talmor D, Clardy P, Ngo L, Shapiro NI: Performance of severity of illness scoring systems in emergency department patients with infection. Acad Emerg Med. 2007, 14: 709-714. 10.1111/j.1553-2712.2007.tb01866.x.CrossRef
17.
go back to reference Sankoff JD, Goyal M, Gaieski DF, Deitch K, Davis CB, Sabel AL, Haukoos JS: Validation of the Mortality in Emergency Department Sepsis (MEDS) score in patients with the systemic inflammatory response syndrome (SIRS). Crit Care Med. 2008, 36: 421-426. 10.1097/01.CCM.0B013E3181611F6A0.CrossRef Sankoff JD, Goyal M, Gaieski DF, Deitch K, Davis CB, Sabel AL, Haukoos JS: Validation of the Mortality in Emergency Department Sepsis (MEDS) score in patients with the systemic inflammatory response syndrome (SIRS). Crit Care Med. 2008, 36: 421-426. 10.1097/01.CCM.0B013E3181611F6A0.CrossRef
18.
go back to reference Becker KL, Snider R, Nylen ES: Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med. 2008, 36: 941-952. 10.1097/CCM.0B013E318165BABB.CrossRef Becker KL, Snider R, Nylen ES: Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med. 2008, 36: 941-952. 10.1097/CCM.0B013E318165BABB.CrossRef
19.
go back to reference Kibe S, Adams K, Barlow G: Diagnostic and prognostic biomarkers of sepsis in critical care. J Antimicrob Chemother. 2011, 66: ii33-ii40. 10.1093/jac/dkr121.CrossRef Kibe S, Adams K, Barlow G: Diagnostic and prognostic biomarkers of sepsis in critical care. J Antimicrob Chemother. 2011, 66: ii33-ii40. 10.1093/jac/dkr121.CrossRef
20.
go back to reference Martensson J, Bell M, Oldner A, Xu S, Venge P, Martling CR: Neutrophil gelatinase- associated lipocalin in adult septic patients with and without acute kidney injury. Intensive Care Med. 2010, 36: 1333-1340. 10.1007/s00134-010-1887-4.CrossRef Martensson J, Bell M, Oldner A, Xu S, Venge P, Martling CR: Neutrophil gelatinase- associated lipocalin in adult septic patients with and without acute kidney injury. Intensive Care Med. 2010, 36: 1333-1340. 10.1007/s00134-010-1887-4.CrossRef
21.
go back to reference Katagiri D, Doi K, Matsubara T: New biomarker panel of plasma neutrophil gelatinase-associated lipocalin and endotoxin activity assay for detecting sepsis in acute kidney injury. J Crit Care. 2013, 28: 564-570. 10.1016/j.jcrc.2013.01.009.CrossRef Katagiri D, Doi K, Matsubara T: New biomarker panel of plasma neutrophil gelatinase-associated lipocalin and endotoxin activity assay for detecting sepsis in acute kidney injury. J Crit Care. 2013, 28: 564-570. 10.1016/j.jcrc.2013.01.009.CrossRef
22.
go back to reference Devarajan P: Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury. Biomark Med. 2010, 4: 265-280. 10.2217/bmm.10.12.CrossRef Devarajan P: Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury. Biomark Med. 2010, 4: 265-280. 10.2217/bmm.10.12.CrossRef
23.
go back to reference Cowland JB, Borregaard N: Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics. 1997, 45: 17-23. 10.1006/geno.1997.4896.CrossRef Cowland JB, Borregaard N: Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics. 1997, 45: 17-23. 10.1006/geno.1997.4896.CrossRef
24.
go back to reference Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, Strong RK, Akira S, Aderem A: Lipocalin 2 mediates an innate immune response to bacterial infection by sequestering iron. Nature. 2004, 432: 917-921. 10.1038/nature03104.CrossRef Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, Strong RK, Akira S, Aderem A: Lipocalin 2 mediates an innate immune response to bacterial infection by sequestering iron. Nature. 2004, 432: 917-921. 10.1038/nature03104.CrossRef
25.
go back to reference Berger T, Togawa A, Duncan GS, Elia AJ, You-Ten A, Wakeham A, Fong HE, Cheung CC, Mak TW: Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coliinfection but not to ischemia-reperfusion injury. Proc Natl Acad Sci U S A. 2006, 103: 1834-1839. 10.1073/pnas.0510847103.CrossRef Berger T, Togawa A, Duncan GS, Elia AJ, You-Ten A, Wakeham A, Fong HE, Cheung CC, Mak TW: Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coliinfection but not to ischemia-reperfusion injury. Proc Natl Acad Sci U S A. 2006, 103: 1834-1839. 10.1073/pnas.0510847103.CrossRef
26.
go back to reference Maitra SR, Jacob A, Zhou M, Wang P: Modulation of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in sepsis. Int J Clin Exp Med. 2010, 3: 180-185. Maitra SR, Jacob A, Zhou M, Wang P: Modulation of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in sepsis. Int J Clin Exp Med. 2010, 3: 180-185.
27.
go back to reference Nagase H, Visse R, Murphy G: Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006, 69: 562-573. 10.1016/j.cardiores.2005.12.002.CrossRef Nagase H, Visse R, Murphy G: Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006, 69: 562-573. 10.1016/j.cardiores.2005.12.002.CrossRef
28.
go back to reference Maitra SR, Shapiro MJ, Bhaduri S, El-Maghrabi MR: Effect of chemically modified tetracycline on transforming growth factor-beta1 and caspase-3 activation in liver of septic rats. Crit Care Med. 2005, 33: 1577-1581. 10.1097/01.CCM.0000169880.82060.F7.CrossRef Maitra SR, Shapiro MJ, Bhaduri S, El-Maghrabi MR: Effect of chemically modified tetracycline on transforming growth factor-beta1 and caspase-3 activation in liver of septic rats. Crit Care Med. 2005, 33: 1577-1581. 10.1097/01.CCM.0000169880.82060.F7.CrossRef
29.
go back to reference Hoffman U, Bertsch T, Dvortsak E, Liebetrau C, Lang S, Liebe V, Huhle G, Borggrefe M, Brueckmann M: Matrix metalloproteinases and their inhibitors are elevated in sepsis. Prognostic value of TIMP-1 in severe sepsis. Scand J Infect Dis. 2006, 38: 867-872. 10.1080/00365540600702058.CrossRef Hoffman U, Bertsch T, Dvortsak E, Liebetrau C, Lang S, Liebe V, Huhle G, Borggrefe M, Brueckmann M: Matrix metalloproteinases and their inhibitors are elevated in sepsis. Prognostic value of TIMP-1 in severe sepsis. Scand J Infect Dis. 2006, 38: 867-872. 10.1080/00365540600702058.CrossRef
30.
go back to reference DI Carlo A: Evaluation of neutrophil gelatinase-associated lipocalin (NGAL), matrix metalloproteinase-9 (MMP-9) and their complex MMP-9/NGAL in sera and urine of patients with kidney tumors. Oncol Lett. 2013, 5: 1677-1681. DI Carlo A: Evaluation of neutrophil gelatinase-associated lipocalin (NGAL), matrix metalloproteinase-9 (MMP-9) and their complex MMP-9/NGAL in sera and urine of patients with kidney tumors. Oncol Lett. 2013, 5: 1677-1681.
31.
go back to reference Lorente L, Martín MM, Labarta L, Díaz C, Solé-Violán J, Blanquer J, Orbe J, Rodríguez JA, Jiménez A, Borreguero-León JM, Belmonte F, Medina JC, Llimiñana MC, Ferrer-Agüero JM, Ferreres J, Mora ML, Lubillo S, Sánchez M, Barrios Y, Sierra A, Páramo JA: Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis. Crit Care. 2009, 13: R158-10.1186/cc8115.CrossRef Lorente L, Martín MM, Labarta L, Díaz C, Solé-Violán J, Blanquer J, Orbe J, Rodríguez JA, Jiménez A, Borreguero-León JM, Belmonte F, Medina JC, Llimiñana MC, Ferrer-Agüero JM, Ferreres J, Mora ML, Lubillo S, Sánchez M, Barrios Y, Sierra A, Páramo JA: Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis. Crit Care. 2009, 13: R158-10.1186/cc8115.CrossRef
32.
go back to reference Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A: Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 2009, 54: 1012-1024. 10.1053/j.ajkd.2009.07.020.CrossRef Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A: Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 2009, 54: 1012-1024. 10.1053/j.ajkd.2009.07.020.CrossRef
33.
go back to reference Bagshaw SM, Bennett M, Devarajan P, Bellomo R: Urine biochemistry in septic and non-septic acute kidney injury: a prospective observational study. J Crit Care. 2013, 28: 371-378. 10.1016/j.jcrc.2012.10.007.CrossRef Bagshaw SM, Bennett M, Devarajan P, Bellomo R: Urine biochemistry in septic and non-septic acute kidney injury: a prospective observational study. J Crit Care. 2013, 28: 371-378. 10.1016/j.jcrc.2012.10.007.CrossRef
Metadata
Title
Diagnostic and prognostic value of neutrophil gelatinase-associated lipocalin, matrix metalloproteinase-9, and tissue inhibitor of matrix metalloproteinases-1 for sepsis in the Emergency Department: an observational study
Authors
Miaomiao Wang
Qian Zhang
Xin Zhao
Guijuan Dong
Chunsheng Li
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Critical Care / Issue 6/2014
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-014-0634-6

Other articles of this Issue 6/2014

Critical Care 6/2014 Go to the issue